RE: Myles Tweet: Updated Avacta18 Aug 2021 19:46
The snippet i liked the most was"In mouse models, the administration of standard doxorubicin resulted in approximately the same concentration of the drug in heart tissue as in tumour tissue. This 1:1 ratio was expected: doxorubicin is not targeted, thus causing dose limiting, severe cardiotoxicity. Conversely AVA6000 – even when administered at a dose 6 times as potent as the control dose of doxorubicin – produced less doxorubicin exposure in the heart, while producing 18 times as much doxorubicin in the target tumour tissue compared with the heart.
This resulted in dramatic tumour shrinkage and a 100% survival rate at 60 days of the mice treated with AVA6000, compared with a 0% survival rate of the mice treated with standard doxorubicin"